<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Subedi GP</submitter><funding>HHS | National Institutes of Health</funding><funding>Roy J. Carver Department of Biochemistry, Biophysics &amp;amp; Molecular Biology</funding><funding>NIGMS NIH HHS</funding><pagination>16842-16850</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6204906</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>293(43)</volume><pubmed_abstract>Fc γ receptors (FcγRs) bind circulating IgG (IgG1) at the surface of leukocytes. Antibodies clustered at the surface of a targeted particle trigger a protective immune response through activating FcγRs. Three recent reports indicate that the composition of the asparagine-linked carbohydrate chains (&lt;i>N&lt;/i>-glycans) of FcγRIIIa/CD16a impacted IgG1-binding affinity. Here we determined how &lt;i>N&lt;/i>-glycan composition affected the affinity of the "low-affinity" FcγRs for six homogeneous IgG1 Fc &lt;i>N&lt;/i>-glycoforms (G0, G0F, G2, G2F, A2G2, and A2G2F). Surprisingly, CD16a with oligomannose &lt;i>N&lt;/i>-glycans bound to IgG1 Fc (A2G2) with a &lt;i>K&lt;sub>D&lt;/sub>&lt;/i> = 1.0 ± 0.1 nm This affinity represents a 51-fold increase over the affinity measured for CD16a with complex-type &lt;i>N&lt;/i>-glycans (51 ± 8 nm) and is comparable with the affinity of FcγRI/CD64, the sole "high-affinity" FcγR. CD16a &lt;i>N&lt;/i>-glycan composition accounted for increases in binding affinity for the other IgG1 Fc glycoforms tested (10-50-fold). This remarkable sensitivity could only be eliminated by preventing glycosylation at Asn&lt;sup>162&lt;/sup> with an Asn-to-Gln mutation; mutations at the four other &lt;i>N&lt;/i>-glycosylation sites preserved tighter binding in the Man5 glycoform. None of the other low-affinity FcγRs showed more than a 3.1-fold increase upon modifying the receptor &lt;i>N&lt;/i>-glycan composition, including CD16b, which differs from CD16a by only four amino acid residues. This result indicates that CD16a is unique among the low-affinity FcγRs, and modifying only the glycan composition of both the IgG1 Fc ligand and receptor provides a 400-fold range in affinities.</pubmed_abstract><journal>The Journal of biological chemistry</journal><pubmed_title>CD16a with oligomannose-type &lt;i>N&lt;/i>-glycans is the only "low-affinity" Fc γ receptor that binds the IgG crystallizable fragment with high affinity &lt;i>in vitro&lt;/i>.</pubmed_title><pmcid>PMC6204906</pmcid><funding_grant_id>R01 GM115489</funding_grant_id><funding_grant_id>R01GM115489</funding_grant_id><funding_grant_id>Start-up funds</funding_grant_id><pubmed_authors>Barb AW</pubmed_authors><pubmed_authors>Subedi GP</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD16a with oligomannose-type &lt;i>N&lt;/i>-glycans is the only "low-affinity" Fc γ receptor that binds the IgG crystallizable fragment with high affinity &lt;i>in vitro&lt;/i>.</name><description>Fc γ receptors (FcγRs) bind circulating IgG (IgG1) at the surface of leukocytes. Antibodies clustered at the surface of a targeted particle trigger a protective immune response through activating FcγRs. Three recent reports indicate that the composition of the asparagine-linked carbohydrate chains (&lt;i>N&lt;/i>-glycans) of FcγRIIIa/CD16a impacted IgG1-binding affinity. Here we determined how &lt;i>N&lt;/i>-glycan composition affected the affinity of the "low-affinity" FcγRs for six homogeneous IgG1 Fc &lt;i>N&lt;/i>-glycoforms (G0, G0F, G2, G2F, A2G2, and A2G2F). Surprisingly, CD16a with oligomannose &lt;i>N&lt;/i>-glycans bound to IgG1 Fc (A2G2) with a &lt;i>K&lt;sub>D&lt;/sub>&lt;/i> = 1.0 ± 0.1 nm This affinity represents a 51-fold increase over the affinity measured for CD16a with complex-type &lt;i>N&lt;/i>-glycans (51 ± 8 nm) and is comparable with the affinity of FcγRI/CD64, the sole "high-affinity" FcγR. CD16a &lt;i>N&lt;/i>-glycan composition accounted for increases in binding affinity for the other IgG1 Fc glycoforms tested (10-50-fold). This remarkable sensitivity could only be eliminated by preventing glycosylation at Asn&lt;sup>162&lt;/sup> with an Asn-to-Gln mutation; mutations at the four other &lt;i>N&lt;/i>-glycosylation sites preserved tighter binding in the Man5 glycoform. None of the other low-affinity FcγRs showed more than a 3.1-fold increase upon modifying the receptor &lt;i>N&lt;/i>-glycan composition, including CD16b, which differs from CD16a by only four amino acid residues. This result indicates that CD16a is unique among the low-affinity FcγRs, and modifying only the glycan composition of both the IgG1 Fc ligand and receptor provides a 400-fold range in affinities.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Oct</publication><modification>2026-05-06T00:17:35.62Z</modification><creation>2019-11-05T08:04:18Z</creation></dates><accession>S-EPMC6204906</accession><cross_references><pubmed>30213862</pubmed><doi>10.1074/jbc.ra118.004998</doi><doi>10.1074/jbc.RA118.004998</doi></cross_references></HashMap>